Globally, innovators are finding the need for speed as the driver for investment, partnering and success: speed to the clinic, speed to early human data, and speed to de-risk assets. The question for European biotechs is what's their best strategy to compete in this arena, facing new momentum from Asia, and an unpredictable landscape in the U.S. As always, the science in Europe is there. There are more experienced operators than ever before. And after four long years, investor sentiment, finally, is turning.

In its 26th edition, Bio€quity Europe travels to Central and Eastern Europe for the first time to explore opportunities in the region, and to debate how European biotech can accelerate to compete — and lead — in today's world.

View the event here.